Feasibility of a Web-Based Platform (Trial My App) to Efficiently Conduct Randomized Controlled Trials of mHealth Apps For Patients With Cardiovascular Risk Factors: Protocol For Evaluating an mHealth App for Hypertension.
app
cardiovascular disease
feasibility
hypertension
internet-administered
mHealth
mobile health
patient-oriented
randomized controlled trial
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
01 Feb 2021
01 Feb 2021
Historique:
received:
05
01
2021
accepted:
08
01
2021
entrez:
1
2
2021
pubmed:
2
2
2021
medline:
2
2
2021
Statut:
epublish
Résumé
Mobile health (mHealth) interventions can improve health by improving cardiovascular risk factors, but their adoption in care by physicians and patients is untapped. Few mHealth apps have been evaluated in clinical trials, and due to the fast pace of technological development, those previously evaluated are often outdated by the time trial results are available. Given the rapid pace of change in this field, it is not feasible to rigorously evaluate mHealth apps with current methodologies. The overall aim of this pilot study was to test the feasibility of using a web research platform called Trial My App to conduct efficient and rigorous web-based randomized controlled trials (RCTs) of mHealth apps relevant to patients with cardiovascular risk factors by evaluating an app that targets hypertension. For this study, 200 participants with suboptimally controlled hypertension will be recruited through advertisements in newsletters, media, and the internet, as well as through referrals from their health care providers. Screening, consent, randomization, and collection of patient-important health confidence and self-management ability outcomes will be conducted online through the Trial My App research platform. Participants will be randomized into 2 groups: 100 that will use an mHealth app for tracking hypertension and 100 that will be considered as an educational control. All participants will complete questionnaires at 0, 1, 3 and 6 months after enrolment. A substudy to validate the method of blood pressure readings and the consistency of data entered through Trial My App will be conducted with 40 participants. The development of the Trial My App web platform has been completed. The creation of survey instruments has been completed in collaboration with our patient partners and advisory board. Recruitment is expected to begin in the first quarter of 2021; data collection and analysis are expected to be completed approximately 1 year after study commencement. Results will be disseminated through conferences and publications. The primary outcomes of this study include the feasibility of conducting an RCT using the Trial My App platform by reporting recruitment, retention, and completion statistics. We will validate app-entered data with a standard 7-day home blood pressure measurement method. Lastly, the pilot, nonblinded RCT will assess the effectiveness of the mHealth app in improving the control of hypertension compared with the control of hypertension in the educational control group. This study will determine if it is feasible to use the Trial My App web-based platform to evaluate the effectiveness of mHealth apps for patients with cardiovascular risk factors. As more mHealth apps are evaluated in RCTs, patients will be able to select apps that meet their needs and physicians will be able to make evidence-based recommendations to their patients for apps aimed at improving cardiovascular health. ClinicalTrials.gov NCT04528654; https://clinicaltrials.gov/ct2/show/NCT04528654. PRR1-10.2196/26155.
Sections du résumé
BACKGROUND
BACKGROUND
Mobile health (mHealth) interventions can improve health by improving cardiovascular risk factors, but their adoption in care by physicians and patients is untapped. Few mHealth apps have been evaluated in clinical trials, and due to the fast pace of technological development, those previously evaluated are often outdated by the time trial results are available. Given the rapid pace of change in this field, it is not feasible to rigorously evaluate mHealth apps with current methodologies.
OBJECTIVE
OBJECTIVE
The overall aim of this pilot study was to test the feasibility of using a web research platform called Trial My App to conduct efficient and rigorous web-based randomized controlled trials (RCTs) of mHealth apps relevant to patients with cardiovascular risk factors by evaluating an app that targets hypertension.
METHODS
METHODS
For this study, 200 participants with suboptimally controlled hypertension will be recruited through advertisements in newsletters, media, and the internet, as well as through referrals from their health care providers. Screening, consent, randomization, and collection of patient-important health confidence and self-management ability outcomes will be conducted online through the Trial My App research platform. Participants will be randomized into 2 groups: 100 that will use an mHealth app for tracking hypertension and 100 that will be considered as an educational control. All participants will complete questionnaires at 0, 1, 3 and 6 months after enrolment. A substudy to validate the method of blood pressure readings and the consistency of data entered through Trial My App will be conducted with 40 participants.
RESULTS
RESULTS
The development of the Trial My App web platform has been completed. The creation of survey instruments has been completed in collaboration with our patient partners and advisory board. Recruitment is expected to begin in the first quarter of 2021; data collection and analysis are expected to be completed approximately 1 year after study commencement. Results will be disseminated through conferences and publications. The primary outcomes of this study include the feasibility of conducting an RCT using the Trial My App platform by reporting recruitment, retention, and completion statistics. We will validate app-entered data with a standard 7-day home blood pressure measurement method. Lastly, the pilot, nonblinded RCT will assess the effectiveness of the mHealth app in improving the control of hypertension compared with the control of hypertension in the educational control group.
CONCLUSIONS
CONCLUSIONS
This study will determine if it is feasible to use the Trial My App web-based platform to evaluate the effectiveness of mHealth apps for patients with cardiovascular risk factors. As more mHealth apps are evaluated in RCTs, patients will be able to select apps that meet their needs and physicians will be able to make evidence-based recommendations to their patients for apps aimed at improving cardiovascular health.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT04528654; https://clinicaltrials.gov/ct2/show/NCT04528654.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/26155.
Identifiants
pubmed: 33522978
pii: v10i2e26155
doi: 10.2196/26155
pmc: PMC7884212
doi:
Banques de données
ClinicalTrials.gov
['NCT04528654']
Types de publication
Journal Article
Langues
eng
Pagination
e26155Informations de copyright
©Cynthia Lokker, Rita Jezrawi, Itzhak Gabizon, Jobin Varughese, Michael Brown, Dan Trottier, Elizabeth Alvarez, Jon-David Schwalm, Michael McGillion, Jinhui Ma, Vinai Bhagirath. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 01.02.2021.
Références
JMIR Mhealth Uhealth. 2015 Nov 04;3(4):e101
pubmed: 26537656
J Am Med Inform Assoc. 2020 Feb 1;27(2):330-340
pubmed: 31599936
Can J Cardiol. 2017 Feb;33(2):219-231
pubmed: 27956043
J Med Internet Res. 2009 Jan 13;11(1):e1
pubmed: 19141433
J Hypertens. 2013 Mar;31(3):455-67; discussion 467-8
pubmed: 23299557
Cochrane Database Syst Rev. 2016 Apr 10;4:CD006611
pubmed: 27060875
Am J Prev Med. 2009 Oct;37(4):263-9
pubmed: 19765496
Circulation. 2015 Sep 22;132(12):1157-213
pubmed: 26271892
Curr Hypertens Rep. 2017 Jun;19(6):48
pubmed: 28501982
BMJ Open Qual. 2019 Jun 7;8(2):e000411
pubmed: 31259277
J Med Internet Res. 2018 May 02;20(5):e177
pubmed: 29720359
Int J Behav Nutr Phys Act. 2018 May 23;15(1):45
pubmed: 29792202
JAMA Netw Open. 2020 Mar 2;3(3):e200255
pubmed: 32119093
Eur Heart J. 2016 May 07;37(18):1428-38
pubmed: 26873093
Implement Sci. 2011 Aug 11;6:94
pubmed: 21834970
J Natl Med Assoc. 2011 Jun;103(6):503-12
pubmed: 21830634
Nat Rev Cardiol. 2015 Jun;12(6):350-60
pubmed: 25801714
Annu Rev Public Health. 2019 Apr 1;40:127-146
pubmed: 30601717
Obesity (Silver Spring). 2013 Jan;21(1):25-31
pubmed: 23505165
Int J Behav Nutr Phys Act. 2011 May 18;8:41
pubmed: 21592351
JAMA Intern Med. 2013 Jan 28;173(2):105-11
pubmed: 23229890
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
J Telemed Telecare. 2018 Jan;24(1):22-30
pubmed: 27760883
NPJ Digit Med. 2018 May 9;1:12
pubmed: 31304297
Jacobs J Community Med. 2016;2(1):
pubmed: 27034992
Can J Cardiol. 2020 May;36(5):596-624
pubmed: 32389335